diseases, is named a HHMI investigator
Dr. Erol Fikrig, a Yale School of Medicine researcher who specializes in
the study and treatment of Lyme disease, West Nile virus and other vector-borne
diseases, has been named a Howard Hughes Medical Institute (HHMI) investigator.
HHMI is a non-profit medical research organization that invests in the support,
training and education of the nation’s most creative and promising scientists.
Its investigators are chosen through rigorous national competitions. The organization
was founded in 1953 by aviator and industrialist Howard R. Hughes.
Fikrig, the Waldemar Von Zedtwitz Professor of Medicine, also studies human granulocytic
ehrlichiosis, a newly described pathogen transmitted by ticks. His research focuses
on molecular strategies the biological agent uses to survive in white blood cells.
(see related story)
“Erol Fikrig is an outstanding scientist who studies the important interactions
between tick-borne bacteria and their vector hosts,” said Dr. Robert Alpern,
dean of the medical school. “These are important scientific and medical
issues, the understanding of which will save lives.”
Fikrig’s research has led to a new understanding of the relationship between
the pathogens that transmit the diseases, the vectors (i.e. organisms) that carry
the pathogens and the hosts they infect. Information from his studies is suggesting
new strategies to prevent and treat Lyme disease, West Nile encephalitis, and
other infections, by interrupting these relationships.
His first project after coming to Yale in 1988 was developing and testing a Lyme
disease vaccine with HHMI investigator Richard Flavell, chair of the Department
of Immunobiology, who remains a frequent collaborator. While the vaccine was
being developed, Fikrig made the first of a series of important discoveries about
the life cycle of the bacterium. He demonstrated that, in moving between the
tick and humans, the bacterium covers itself with a protein drawn from the tick’s
saliva. That protein helps the bacterium avoid attack by the human immune system.
Fikrig also discovered that the bacterium has a way of inducing the tick to make
more of the protective saliva protein. That finding has led Fikrig to investigate
the ways human pathogens interact with their environments, often by manipulating
the biological mechanisms of their hosts. Through his studies he has uncovered
new ways to disrupt pathogens at various stages in their life cycles, not just
when they are infecting humans.
T H I S
SCHOOL OF MEDICINE NEWS
W E E K ' SS T O R I E S
Restoration of iconic Rudolph building is key step in . . . Arts Complex
Three faculty win nation’s highest award for beginning researchers
Bulldogs, Crimsons both bringing undefeated Ivy records . . .
A grateful nation
New technology allows view of protein interactions in living cells
Monkeys and children share adults’ tendency to rationalize choices
Noted composer Benjamin Lees donates his archive to Yale library
Museum joins with area public schools to promote ‘visual literacy’
A conversation in China leads to successful research collaboration
Junior faculty earn second terms in endowed posts
Study: Simple measures could prevent spread of . . . tuberculosis
Erol Fikrig, specialist in vector-borne diseases . . .
Physical and emotion stress linked to aortic rupture
Groundbreaking scientist joins Yale Stem Cell Center
Team develops blood test for deadly aneurysm disease
Workshop will showcase new Positron Emission Tomography Center
Four decades of readers in Yale libraries are featured in exhibition
Video installations by Ori Gersht on view at British Art Center
Reception will celebrate United Way donors as campaign continues
Yale Books in Briefs
Benefit event to feature noted neurosurgeon
Workshop to feature Ohio State law professor
Reminder: Open enrollment period ends Nov. 18
Campus Notes
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home